Needham & Company LLC restated their buy rating on shares of Immuneering (NASDAQ:IMRX – Free Report) in a report issued on Friday, Benzinga reports. Needham & Company LLC currently has a $15.00 price objective on the stock.
Separately, Chardan Capital decreased their price objective on Immuneering from $16.00 to $12.00 and set a buy rating for the company in a research report on Wednesday, August 7th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Immuneering has a consensus rating of Moderate Buy and a consensus target price of $12.60.
Get Our Latest Stock Analysis on IMRX
Immuneering Trading Up 41.3 %
Immuneering (NASDAQ:IMRX – Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.05. As a group, equities analysts forecast that Immuneering will post -1.9 EPS for the current year.
Hedge Funds Weigh In On Immuneering
Several hedge funds have recently made changes to their positions in IMRX. XTX Topco Ltd grew its stake in Immuneering by 37.3% in the second quarter. XTX Topco Ltd now owns 34,159 shares of the company’s stock valued at $44,000 after purchasing an additional 9,274 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Immuneering in the second quarter valued at $44,000. Acadian Asset Management LLC acquired a new position in Immuneering during the second quarter worth $67,000. Vanguard Group Inc. raised its position in Immuneering by 12.1% during the first quarter. Vanguard Group Inc. now owns 1,203,666 shares of the company’s stock worth $3,479,000 after acquiring an additional 129,851 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in Immuneering in the second quarter valued at $447,000. 67.65% of the stock is owned by institutional investors.
Immuneering Company Profile
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.
Further Reading
- Five stocks we like better than Immuneering
- 3 Stocks to Consider Buying in October
- Powering Your Portfolio: The Utility Sector’s Electrifying Surge
- Dividend Capture Strategy: What You Need to Know
- Adobe Stock Builds Long-Term Value: Consider Buying on the Dip
- The Basics of Support and Resistance
- Albemarle Jumps as Lithium Stock Buying Frenzy Takes Off
Receive News & Ratings for Immuneering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuneering and related companies with MarketBeat.com's FREE daily email newsletter.